scroll to top
0

EBSCO Auth Banner

Let's find your institution. Click here.

Advanced Search Results For "glioblastoma"

1 - 10 of 59,801 results for
 "glioblastoma"
Results per page:

PUF60 promotes glioblastoma progression through regulation of EGFR stability.

Publication Type: Academic Journal

Source(s): Biochemical and biophysical research communications [Biochem Biophys Res Commun] 2022 Dec 25; Vol. 636 (Pt 1), pp. 190-196. Date of Electronic Publication: 2022 Oct 29.

Authors:

Abstract: PUF60 (Poly (U) binding splicing factor 60 kDa), a nucleic acid-binding protein, has been shown to regulate transcription and links to tumorigenesis in various cancers. However, its biological role and function in glioblastoma remain unknown. In this s...

View details

Preclinical gene therapy in glioblastoma multiforme: Using olfactory ensheathing cells containing a suicide gene.

Publication Type: Academic Journal

Source(s): Life sciences [Life Sci] 2022 Dec 15; Vol. 311 (Pt A), pp. 121132. Date of Electronic Publication: 2022 Oct 27.

Abstract: Aims: Glioblastoma multiforme (GBM) is the most malignant type of brain tumor resistant to current treatments. Recently, suicide gene therapy with the Herpex Simplex Virus thymidine kinase (HSV-tk) gene has been developed with high therapeutic potency,...

View details

Strategies, considerations, and recent advancements in the development of liquid biopsy for glioblastoma: a step towards individualized medicine in glioblastoma.

Publication Type: Academic Journal

Source(s): Neurosurgical focus [Neurosurg Focus] 2022 Dec; Vol. 53 (6), pp. E14.

Abstract: Objective: Glioblastoma (GBM) is a devasting primary brain tumor with less than a 5% 5-year survival. Treatment response assessment can be challenging because of inflammatory pseudoprogression that mimics true tumor progression clinically and on imagin...

View details

Clinical Benefit of Bevacizumab and Irinotecan (BEV+IRI) in Patients With Relapsed/Refractory Glioblastoma (r/rGBM) and its Potential Predictors.

Publication Type: Academic Journal

Source(s): Anticancer research [Anticancer Res] 2022 Dec; Vol. 42 (12), pp. 6091-6098.

Abstract: Background/aim: Bevacizumab-containing chemotherapy constitutes an important salvage treatment for recurrent/refractory glioblastoma(r/rGBM).Patients and Methods: We retrospectively collected the data of r/rGBM patients treated with the combination of ...

View details

CHI3L1 predicted in malignant entities is associated with glioblastoma immune microenvironment.

Publication Type: Academic Journal

Source(s): Clinical immunology (Orlando, Fla.) [Clin Immunol] 2022 Dec; Vol. 245, pp. 109158. Date of Electronic Publication: 2022 Oct 14.

Authors:

Abstract: Effective immunotherapies for patients with glioblastoma (GBM) are urgently needed. Chitinase-3 like-protein-1 (CHI3L1) play important roles in the development of gliomas. However, its role in glioma-related immune responses remains unclear. We aimed t...

View details

Decitabine increases neoantigen and cancer testis antigen expression to enhance T-cell-mediated toxicity against glioblastoma.

Publication Type: Academic Journal

Source(s): Neuro-oncology [Neuro Oncol] 2022 Dec 01; Vol. 24 (12), pp. 2093-2106.

Abstract: Background: Glioblastoma (GBM) is the most common and malignant primary brain tumor in adults. Despite maximal treatment, median survival remains dismal at 14-24 months. Immunotherapies, such as checkpoint inhibition, have revolutionized management of ...

View details

Quantitative measurement of peritumoral concentrations of glutamate, N-acetyl aspartate, and lactate on magnetic resonance spectroscopy predicts glioblastoma-related refractory epilepsy.

Publication Type: Academic Journal

Source(s): Acta neurochirurgica [Acta Neurochir (Wien)] 2022 Dec; Vol. 164 (12), pp. 3253-3266. Date of Electronic Publication: 2022 Sep 15.

Abstract: Background: Increased extracellular glutamate is known to cause epileptic seizures in patients with glioblastoma (GBM). However, predicting whether the seizure will be refractory is difficult. The present study investigated whether evaluation of the le...

View details

MicroRNA-219 loaded chitosan nanoparticles for treatment of glioblastoma.

Publication Type: Academic Journal

Source(s): Artificial cells, nanomedicine, and biotechnology [Artif Cells Nanomed Biotechnol] 2022 Dec; Vol. 50 (1), pp. 198-207.

Abstract: Recent evidence has implicated microRNA-219 (miR-219) in regulation of gene contributed in glioblastoma (GBM) pathogenesis. This study aimed to prepare miR-219 in chitosan (CS) nanoparticles (NPs), characterize and investigate their efficacy on human G...

View details

The miR-429 suppresses proliferation and migration in glioblastoma cells and induces cell-cycle arrest and apoptosis via modulating several target genes of ERBB signaling pathway.

Publication Type: Academic Journal

Source(s): Molecular biology reports [Mol Biol Rep] 2022 Dec; Vol. 49 (12), pp. 11855-11866. Date of Electronic Publication: 2022 Oct 11.

Abstract: Background: Glioblastoma multiforme (GBM) is an aggressive and lethal brain cancer, which is incurable with standard cancer treatments. miRNAs have great potential to be used for gene therapy due to their ability to modulate several target genes simult...

View details

Functional outcomes, extent of resection, and bright/vague fluorescence interface in resection of glioblastomas involving the motor pathways assisted by 5-ALA.

Publication Type: Academic Journal

Source(s): Acta neurochirurgica [Acta Neurochir (Wien)] 2022 Dec; Vol. 164 (12), pp. 3267-3274. Date of Electronic Publication: 2022 Sep 10.

Abstract: Background: 5-Aminolevulinic acid (5-ALA) fluorescence can maximize perirolandic glioblastoma (GBM) resection with low rates of postoperative sequelae. Our purpose was to present the outcomes of our experience and compare them with other literature rep...

View details
sponsored